Skip to main content
BerGenBio logo

BerGenBio — Investor Relations & Filings

Ticker · BGBIO ISIN · NO0013711713 LEI · 213800TYYFXKYF3V2A23 OL Manufacturing
Open in API
Filings indexed 961 across all filing types
Latest filing 2024-09-09 Regulatory Filings
Country NO Norway
Listing OL BGBIO

About BerGenBio

https://www.bergenbio.com/

BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.

Recent filings

Filing Released Lang Actions
BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference
Regulatory Filings Classification · 99% confidence The document explicitly states that BerGenBio will 'Present Company Update' at the 'H.C. Wainright Annual Global Investment Conference'. It mentions that the CEO will provide a business update and, crucially, states: 'The presentation used at the conference is available in the investor section of the Company's website'. This structure—announcing participation in an external investor event and pointing to the presentation materials elsewhere—is characteristic of an Investor Presentation (IP) announcement, or if the presentation itself is the focus, the presentation material. Since the text is an announcement about presenting, and the presentation itself is the core content being referenced, 'Investor Presentation' (IP) is the most fitting category for the material being discussed, even though this specific text is the announcement of that presentation. Given the context of financial reporting categories, this is an announcement related to investor engagement materials.
2024-09-09 English
BerGenBio Second Quarter Results 2024: Solid clinical and financial progress
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report Q2 and half year 2024' and contains comprehensive financial statements, including the condensed consolidated statement of profit and loss, cash flow analysis, and management's review of financial results for the period ending June 30, 2024. It is a substantive financial report rather than an announcement or certification, fitting the definition of an Interim/Quarterly Report. H1 2024
2024-08-21 English
BerGenBio Second Quarter Results 2024: Solid clinical and financial progress
Earnings Release Classification · 100% confidence The document explicitly announces 'BerGenBio Second Quarter Results 2024' and provides key financial highlights and business updates for the period ended June 30, 2024. This content aligns perfectly with the definition of an Interim/Quarterly Report (IR). Although it mentions that the 'Q2 2024 Financial report is attached to this stock exchange announcement' and refers to a presentation, the document itself contains the substantive results summary, CEO commentary, and financial figures (e.g., cash position, operating expenses), making it more than just a simple announcement of publication (RPA). Therefore, it is classified as the Interim Report itself. Q2 2024
2024-08-21 English
BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m Non-Small Cell Lung Cancer
Regulatory Filings Classification · 100% confidence The document is a press release dated August 20, 2024, announcing a collaboration between BerGenBio and Tempus regarding the clinical development of a drug (bemcentinib) for NSCLC patients. It details a partnership to use real-world data to benchmark a clinical trial (BGBC016). This type of announcement, detailing strategic business or clinical development updates that are not standard periodic financial reports (like 10-K or IR) or specific transactional events (like M&A or Director's Dealing), typically falls under general regulatory announcements or investor news. Since it is a specific announcement of a strategic partnership and clinical development plan, and does not fit the definitions for ER, CAP, LTR, or TAR, it is best classified as a general Regulatory Filing (RNS) or potentially a general Investor Relations document. Given the context of corporate filings, RNS serves as the appropriate catch-all for significant, non-standard corporate news releases that must be disclosed.
2024-08-20 English
BerGenBio ASA: Registration of share capital reduction
Share Issue/Capital Change Classification · 98% confidence The document explicitly announces the 'Registration of share capital reduction' following a resolution passed at a general meeting. It details the change in share capital structure (nominal value reduction) and confirms registration with the Norwegian Register of Business Enterprises. This action directly relates to a change in the company's capital structure, specifically involving shares. Based on the definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate category for formal announcements regarding changes to the company's share capital structure, even if it is a reduction rather than an issuance.
2024-08-15 English
BerGenBio ASA: Invitation to second quarter and half year 2024 results webcast
Report Publication Announcement Classification · 98% confidence The document is a short announcement explicitly titled 'Invitation to second quarter and half year 2024 results webcast'. It states that the company 'will be announcing its results for the second quarter and half year 2024 on Wednesday 21 August 2024' and provides details on when the financial report and presentation will be made available. Since the document itself is an announcement about the upcoming release of financial results and a webcast, and it is very short (under 5,000 characters), it fits the definition of a Report Publication Announcement (RPA) rather than the comprehensive Interim Report (IR) or Earnings Release (ER) itself. It is announcing the publication of the results.
2024-08-13 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.